Position in TRVI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$276,467
+$129,872 QoQ
Shares Held
14,824
+20.6% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#155
of 216 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TRVI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Rafferty Asset Management, LLC holds $331,711,589 across 163 Biotechnology names. TRVI ranks #133 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
65,798 | $32,683,840 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
38,534 | $24,027,490 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
55,332 | $16,656,591 | |
| 4 | MRNA |
Moderna, Inc.
|
111,906 | $7,836,777 | |
| 5 | INCY |
Incyte Corp
|
44,663 | $5,062,997 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
33,369 | $4,429,067 | |
| 7 | ORKA |
Oruka Therapeutics, Inc.
|
43,110 | $4,102,778 | |
| 8 | KYMR |
Kymera Therapeutics, Inc.
|
35,287 | $4,046,360 |
All Filings in TRVI
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $276,467 | 14,824 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $146,595 | 12,288 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $206,567 | 16,499 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $124,128 | 13,566 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $60,077 | 10,983 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||